RABMS Journal of Research in Applied and Basic Medical Sciences

Urmia University of Medical Sciences

High Sensitivity C-Reactive Protein (hs-CRP) and Uric Acid as Markers of Cardiovascular Risk in Chronic Kidney Disease Patients

Thammisetty Anil Kumar[1], Lakshmi Keerthana Badam[2], Bhagya Lakshmi Vanapalli[3]*

[1] Associate professor, Department of Biochemistry, Andaman and Nicobar Islands Institute of Medical Sciences (ANIIMS), Port Blair, A&N Islands, India

[2] Assistant Professor, Department of Biochemistry, Rangaraya Medical College, Kakinada, Andhra Pradesh, India

[3] Professor & HOD, Department of Biochemistry, Rangaraya Medical College, Kakinada, Andhra Pradesh, India

*Corresponding author: Dr.V.Bhagya Lakshmi, **Address**: Department of Biochemistry, Rangaraya Medical College, Kakinada, Andhra Pradesh, India, **Email**: biochem2102@gmail.com, **Tel**: +917095993972

Abstract

Background & Aims: The link between Chronic Kidney Disease (CKD) and Cardio Vascular Disease (CVD) has long been established. Hyperuricemia and inflammatory markers such as hs-CRP are considered to be non-traditional risk factors for cardiovascular risk in CKD patients. The aim of this study was to estimate serum hs-CRP and uric acid levels in patients with chronic kidney disease along with age and sex matched healthy controls and see whether they are statistically significant or not.

Materials & Methods: In this case-control study, totally 30 cases with ages varied from 30-70 years and 30 age and sex matched controls were selected based on inclusion and exclusion criteria. Serum CRP and Uric Acid were analyzed on Beckman Coulter AU-480 fully *automated* analyser, by Turbidimetric end point method and Modified Trinder end point method, respectively. Qualitative data is expressed as proportion and percentage while quantitative data is expressed as mean+SD. Statistical analysis is done using Microsoft Excel sheet and Graph pad software. A *p value <0.05* is considered as statistically significant.

Results: Results show that the patients with CKD had higher levels of hs-CRP and Uric Acid than healthy controls, implying a higher risk of cardiovascular disease in this group.

Conclusion: The present study implies that regular monitoring of these biomarkers is required in CKD patients, to assess the progression of atherosclerosis and evaluate potential interventions, thereby preventing morbidity & mortality due to cardiovascular disease.

Keywords: Chronic Kidney Disease, Serum hs-CRP, Serum Uric Acid

Introduction

The link between Chronic Kidney Disease (CKD) and Cardio Vascular Disease (CVD) has long been established. This association was first suggested by Richard Bright in the early 19th century and has been substantiated in the intervening years. However, the subject has been gaining more attention in recent years (1). Patients with CKD exhibit a pronounced risk for

cardiovascular events: 50% of all patients with CKD stages 4 to 5 have CVD and cardiovascular mortality accounts for ≈40% to 50% of all deaths in patients with advanced CKD (stage 4) as well as end-stage kidney disease (stage 5), compared with 26% in controls with normal kidney function (2). In addition to the high risk for atherosclerosis-related complications such as myocardial infarction and stroke, cardiovascular death also results from heart failure (HF) and fatal arrhythmias, particularly in advanced CKD stages (3,4). In more than 70 studies in nondialyzed subjects with CKD, correction for classical increasing age, hypertension, dyslipidemia, diabetes, smoking and obesity did not neutralize the impact of CKD on cardiovascular risk (5).

Thus, the increased incidence of CVD in CKD is only partially accounted for by the higher prevalence of traditional risk factors. This has turned the attention on the non-traditional or the 'novel' risk factors unique to CKD (6). The non-traditional or 'novel' risk factors are 'uremia specific', or at least much more common in patients with CKD than in the general population. These include albuminuria, anaemia, hyperparathyroidism, metabolic bone disease, hyperhomocysteinaemia, malnutrition, apolipoprotein isoforms, inflammation, endothelial dysfunction and oxidative stress. The various risk factors traditional and non-traditional tend to have an additive effect and hasten atherosclerosis and progression of CKD (7, 8).

From the above, it is derived that hyperuricemia and inflammatory markers such as hs-CRP are considered to be non-traditional risk factors for cardiovascular risk in CKD patients. Uric acid is the end product of purine catabolism. Many epidemiologic studies have revealed that hyperuricemia may be another potential risk factor for cardiovascular mortality in individuals with CKD (9–11). Elevated serum uric acid (SUA) is related to the development and progression of hypertension (12), stroke (13), and cardiovascular disease (14). C-reactive protein is an acute phase reactant that belongs to the protein family known as pentraxin. It is synthesized by the liver in response to cytokines such as interleukin-1, interleukin-6, tumour necrosis factor-alpha released

from macrophages and adipocytes. Elevated serum C-reactive protein (CRP) levels have been shown to be linked with the development of atherosclerosis in CKD patients (15). Analysis of hs-CRP and Uric Acid in serum is relatively easy, less time consuming and also cost-effective. Hence these two markers are selected for the current study.

Many epidemiological studies are carried out throughout the world linking hs-CRP and uric acid independently with cardiovascular risk in CKD patients (16). However, such studies are limited in India. Few studies such as a population-based study of two major cities in North and South India, which found that CKD is evident in 8.7% of the adult population, are available. This study used two common cardiovascular risk scores which classified nearly a third to half of participants with CKD as high risk for experiencing a cardiovascular event (17). Besides, literature search did not yield any research articles, which involved both these biomarkers in a single study. Hence to address the above paucity, the present study is undertaken to measure serum hs-CRP and Uric Acid levels as markers of cardiovascular risk in CKD patients, attending a Tertiary Care Centre in Kakinada district of Andhra Pradesh, India. The aim of this study was to know the variations in serum hs-CRP and Uric Acid, which are the established markers of cardiovascular risk, in patients with chronic kidney disease and compare them with that of healthy controls. The objectives of the study were included estimating serum hs-CRP levels in patients with chronic kidney disease, estimating serum Uric Acid levels in patients with chronic kidney disease, comparing the above values with age and sex matched healthy controls and see whether they are statistically significant or not.

Materials & Methods

(i) Study Design: This is a cross-sectional study planned in Rangaraya Medical College/Government General Hospital, Kakinada, AP, to assess the prevalence of elevated hs-CRP and Uric Acid levels among CKD patients at a single point from April 2023 to July 2023.

(ii) Study Area: The study was conducted among the confirmed cases of Chronic Kidney Disease and healthy controls for whom the investigations are done in Central lab, Department of Biochemistry, Government General Hospital.

(iii) Study Period: The study is conducted for a period of 3 months from April 2023 to July 2023.

(iv) Study Subjects: A total of 60 individuals between the age group 30-70 yrs, both males & females are included in the present study. They are divided into 2 groups as follows:

Group 1: 30 cases who were confirmed cases of chronic kidney disease.

Group 2: 30 controls who were age and sex matched healthy controls.

(a) Inclusion criteria: All the individuals who have given consent/ willing to participate are included in the present study.

(b) Exclusion criteria included Individuals who did not give consent/ not willing to participate in the present study. Also individuals with any co-morbid conditions like Gout, Malignancy, Chronic infections, Acute myocardial infarction, Chronic illness like renal and cardiovascular diseases, Patients on chronic dialysis, Inflammatory conditions like SLE, RA, Smokers, and obesity were excluded from study brcause of their interfere with the study's outcomes.

(v) Ethical approval & Informed consent: Ethical approval is obtained from the Institutional Ethical Committee before the start of the study. Informed consent is obtained from the study subjects before blood sample collection.

(vi) Estimation of biochemical markers: Serum CRP and Uric Acid were analyzed on Beckman Coulter AU-480 fully automated analyser, by Turbidimetric end point method and Modified Trinder end point method respectively. Grossly hemolysed or lipemic or icteric samples were not used for analysis in the present study and are discarded. Internal quality control monitoring using the standards provided in the kit are run. Samples are analyzed only after the daily internal quality control has been passed. The values so obtained are noted in an excel sheet.

(vii) Statistical analysis: Qualitative data is expressed as proportion and percentage while quantitative data is expressed as mean+SD. p value was calculated using student t-test. *p value <0.05* was considered as statistically significant and p value <0.0001 was considered as extremely statistically significant. Statistical analysis was done using Microsoft Excel sheet and Graph pad software.

Results

The results of the present study are presented in Tables 1-3. The study population consisted of 30 patients with CKD (21 males, 9 females) and 30 healthy controls (19 males, 11 females). The mean age of the CKD patients was 54.27 ± 10.11 years, compared to 52.20 ± 9.53 years for the controls. Notably, serum creatinine, hs-CRP, and uric acid levels were significantly elevated in CKD patients relative to controls ($p < 0.0001$ for all comparisons), as detailed in Tables 4 and 5.

Table 1. Gender distribution of cases and control group

Category	Cases	Percentage	Controls	Percentage
Males	21	70	19	63
Females	09	30	11	37
Total	30	100	30	100

Table 2. Comparison of Age in cases and control group

Category	Range (Years)	Mean (Years)	S.D
Cases n = 30	32 – 69	54.27	$\pm$ 10.11
Controls n = 30	34 – 66	52.20	$\pm$ 9.53

Table 3. Comparison of serum Creatinine levels in cases and control group

Category	Range (mg/dl)	Mean (mg/dl)	S.D
Cases n = 30	4.2 – 12.7	7.72	$\pm$ 2.31
Controls n = 30	0.5 – 1.3	0.92	$\pm$ 0.22
		p < 0.0001	

Table 4. Comparison of serum hs-CRP levels in cases and control group

Category	Range (mg/L)	Mean (mg/L)	S.D
Cases n = 30	2.3 – 6.4	4.12	$\pm$ 1.06
Controls n = 30	0.4 – 2.1	1.00	$\pm$ 0.45
		p < 0.0001	

Table 5. Comparison of serum Uric Acid levels in cases and control group

Category	Range (mg/dl)	Mean (mg/dl)	S.D
Cases n = 30	7.1 – 11.8	8.13	$\pm$ 1.17
Controls n = 30	3.7 – 7.0	5.29	$\pm$ 0.90
		p < 0.0001	

Discussion

Cardiovascular disease (CVD) is a major cause of morbidity and mortality in chronic kidney disease (CKD) patients, accounting for about 40% of hospitalizations and 50% of deaths across all CKD stages (18, 19). The CVD process likely initiates in early CKD stages, with both traditional and non-traditional risk factors contributing to its development (20-23).

CKD patients face increased cardiovascular risk due to several factors: higher prevalence of risk factors, CKD itself being an independent risk factor, and the bidirectional relationship between CVD and CKD progression (24-26). Recent guidelines consider CKD a cardiovascular risk equivalent, placing all CKD patients in the "highest risk group" for CVD development (27, 28).

Serum hs-CRP levels:

Our study shows elevated serum hs-CRP levels in CKD patients compared to healthy controls, aligning with recent research. The Modification of Diet in Renal Disease (MDRD) study found high CRP levels to be an independent CVD risk factor in CKD patients (29). However, some studies, like the Cardiovascular Health Study (30) and Irbesartan Diabetic Nephropathy Trial (31), found conflicting results, possibly due to differences in participant risk profiles.

Albert et al. (32) demonstrated hs-CRP's value in predicting cardiovascular risk, while longitudinal analyses of the MDRD Study (33) and Nurses' Health Study (34) further supported its predictive role in CKD patients.

Mechanisms of increased hs-CRP:

Inflammation plays a crucial role in atherosclerosis pathogenesis, with CRP potentially mediating key processes (35-38). In CKD patients, both traditional and CKD-specific risk factors contribute to inflammation (Cottone et al., 2008; Silverstein, 2009). The chronic, low-grade inflammation in CKD is characterized by moderate levels of inflammatory mediators (Ramirez et al., 2006; Furman et al., 2019).

Hs-CRP can bind to damaged endothelial cells, aggregate LDL, and stimulate tissue factor production, increasing cardiovascular events. It also shows an inverse association with creatinine clearance and may contribute to glomerulosclerosis (39). Kopel et al. (40) demonstrated significant vascular endothelial dysfunction in advanced CKD patients.

Serum Uric Acid levels:

Our study shows increased serum uric acid levels in CKD patients compared to healthy controls. This finding is consistent with several recent studies:

- Weiner et al. (41) reported uric acid as an independent predictor of cardiovascular outcomes in stages 3-5 CKD patients.
- A meta-analysis of 12 randomized controlled trials found lower CKD progression and mortality risk in patients receiving uric acid-lowering therapy (44).
- Wen et al. (45) found higher serum uric acid levels to be a risk factor for all-cause and cardiovascular mortality in a large Taiwanese cohort.
- Meta-analyses have shown associations between hyperuricemia and increased risk of cardiovascular mortality, stroke mortality, and cardiovascular events (46-49).
- Madero et al. (50) found higher uric acid levels associated with higher all-cause and cardiovascular-related mortality in CKD stages III and IV patients.

Mechanisms of increased uric acid:

Several mechanisms support the pathogenic association between higher serum uric acid levels and cardiovascular mortality risk:

- Hyperuricemia may disturb mitochondrial function, induce oxidative stress, and stimulate inflammatory responses (51-53).
- Chronically elevated uric acid levels could cause structural changes in vessel walls and contribute to endothelial dysfunction (54).
- Vascular stiffness may be one mechanism by which hyperuricemia increases CVD risk (55-59).
- Elevated uric acid levels have been associated with greater lipid content in coronary plaques and coronary artery calcification (60-63).

Study limitations include small sample size, short duration, and lack of control for confounding factors. However, this research addresses an important area by measuring two biomarkers in a single study. Future large-scale studies are needed to validate these findings.
.

Conclusion

Our study demonstrates elevated levels of serum hs-CRP and uric acid in CKD patients, highlighting the importance of regular monitoring of these biomarkers. These findings suggest that:

1. Regular assessment of hs-CRP and uric acid levels in CKD patients may help evaluate the progression of atherosclerosis and guide potential interventions.
2. Early detection of increased levels of these biomarkers could enhance prompt diagnosis of cardiovascular events, potentially improving outcomes, quality of life, and reducing disease burden and hospitalization rates.
3. The results provide new insights into the relationship between hs-CRP and uric acid as easily measurable markers of cardiovascular risk in CKD patients.

While our study has limitations, including small sample size and short duration, it addresses an important area of research by measuring two biomarkers in a single study. Future large-scale observational studies and clinical trials are needed to further validate these findings and draw more generalizable conclusions.

Conflict of interest:

The authors declare no conflict of interest in relation to this study.

References

1 .Bright R. Cases and observations, illustrative of renal disease, accompanied with the secretion of albuminous urine. Guys Hosp Trans 1836:338- 79.

2 .Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007;72:92-9. https://doi.org/10.1038/sj.ki.5002273

3 .Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M; Alberta Kidney Disease Network. Cause of death in patients with reduced kidney function. J Am Soc Nephrol 2015; 26:2504-11. https://doi.org/10.1681/ASN.2014070714

4 .Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017; 389:1238-52. https://doi.org/10.1016/S0140-6736(16)32064-5

5 .Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 suppl 3):S112-9. https://doi.org/10.1053/ajkd.1998.v32.pm9820470

6 .Sjoblom P, Nystrom FH, Lanne T, Engvall J, Ostgren CJ. Microalbuminuria, but not reduced eGFR, is associated with cardiovascular subclinical organ damage in type 2 diabetes. Diabetes Metab 2014;40:49-55. https://doi.org/10.1016/j.diabet.2013.09.008

7 .Nasrallah R, Hassouneh R, Hébert RL. PGE2, kidney disease, and cardiovascular risk: beyond hypertension and diabetes. J Am Soc Nephrol 2016;27:666-76. https://doi.org/10.1681/ASN.2015050528

8 .Sedaghat S, Mattace-Raso FU, Hoorn EJ, et al. Arterial stiffness and decline in kidney function. Clin J Am Soc Nephrol 2015;10:2190-7. https://doi.org/10.2215/CJN.03000315

9 .Wachtell K, Olsen MH. Is it time to change the definition of normal urinary albumin excretion? Nat Clin Pract Nephrol 2008;4:650-51. https://doi.org/10.1038/ncpneph0971

10 .Dalrymple LS, Katz R, Kestenbaum B , et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011;26:379-85. https://doi.org/10.1007/s11606-010-1511-x

11 .Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-

Angiotensin system in kidney physiology. Compr Physiol 2014;4:1201-28. https://doi.org/10.1002/cphy.c130040

12 .Lopez-Giacoman S, Madero M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol 2015; 4(1):57. https://doi.org/10.5527/wjn.v4.i1.57

13 .Price AM, Ferro CJ, Hayer MK, Steeds RP, Edwards NC, Townend JN. Premature coronary artery disease and early stage chronic kidney disease. QJM In J Med 2018;111(10):683-6. https://doi.org/10.1093/qjmed/hcx179

14 .Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293(14):1737-45. https://doi.org/10.1001/jama.293.14.1737

15 .Nakamura K, Nakagawa H, Murakami Y, et al. Smoking increases the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease. Kidney Int 2015;88(5):1144-52. https://doi.org/10.1038/ki.2015.212

16 .Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2013;107(1):87-92. https://doi.org/10.1161/01.CIR.0000042700.48769.59

17 .Venugopal SK, Devaraj S, Yuhanna I, et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41. https://doi.org/10.1161/01.CIR.0000033116.22237.F9

18 .Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000;15(Suppl 5):69-80 https://doi.org/10.1093/ndt/15.suppl_5.69

19 .Foley RN, Parfey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;339:841-3. https://doi.org/10.1053/ajkd.1998.v32.pm9820470

20 .Arici M, Walls J. End stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 2001; 9:407-17. https://doi.org/10.1046/j.1523-1755.2001.059002407.x

21 .Whaley-Connell AT, Sowers JR, Stevens LA, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey

(NHANES) 1999-2004. Am J Kidney Dis 2008;51:S13-20. https://doi.org/10.1053/j.ajkd.2007.12.016

22 .Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-38. https://doi.org/10.1681/ASN.2004080656

23 .Gansevoort RT, Correa-Rotter R, Hemmelgarn BR et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-52. https://doi.org/10.1016/S0140-6736(13)60595-4

24 .Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293:1737-45. https://doi.org/10.1001/jama.293.14.1737

25 .Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731):2073-81. https://doi.org/10.1016/S0140-6736(10)60674-5

26 .Cachofeiro V, Goicochea M, de Vinuesa SG, et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008;74:S4-S9. https://doi.org/10.1038/ki.2008.516

27 .Orth SR, Hallan SI. Risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or

evidence ofAbsence? Clin J Am Soc Nephrol 2008;3(1):226-36.

28 .Manjunath G, Tighiouart H, Coresh J et al. Level of kidney function as a risk factor for

Cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-9. https://doi.org/10.1046/j.1523-1755.2003.00838.x

29 .Agharazii M, St-Louis R, Gautier-Bastien A, Ung RV, Mokas S, Larivière R, Richard DE. Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification. Am J Hypertens 2015;28:746-55. https://doi.org/10.1093/ajh/hpu225

30 .Fujii H, Goto S, Fukagawa M. Role of uremic toxins for kidney, cardiovascular, and bone dysfunction. Toxins 2018;10:202-220. https://doi.org/10.3390/toxins10050202

31 .Friedman AN, Hunsicker LG, Selhub J, et al. C-reactive protein as a predictor of total

arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 2005;68:773-8. https://doi.org/10.1111/j.1523-1755.2005.00456.x

32 .Albert MA, Glynn RJ, Ridker PM (2003) Plasma concentration of c-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108:161-5. https://doi.org/10.1161/01.CIR.0000080289.72166.CF

33 .MENON V, GREENE T, WANG X, et al: C-reactive protein and serum albumin as predictors of all-cause and cardiovascular mortality in patients with chronic kidney disease. Kidney Int 2005;68:766-72. https://doi.org/10.1111/j.1523-1755.2005.00455.x

34 .Knight EL, Rimm EB, Pai JK, et al: Kidney dysfunction, inflammation, and coronary events: A prospective study. J Am Soc Nephrol 2004;15:1897-1903. https://doi.org/10.1097/01.ASN.0000128966.55133.69

35 .Stenvinkel P, Ketteler M, Johnson RJ, et al: IL-10, IL-6, and TNF alpha: Central factors in the altered cytokine network of uremia. The good, the bad, and the ugly. Kidney Int 2005;67:1216-33. https://doi.org/10.1111/j.1523-1755.2005.00200.x

36 .Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by

macrophages: implications for atherosclerosis. Circulation 2001;103:1194-7.
https://doi.org/10.1161/01.CIR.103.9.1194

37 .Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
https://doi.org/10.1161/01.CIR.0000029802.88087.5E

38 .Qamirani E, Ren Y, Kuo L, et al. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase.
Arterioscler Thromb Vasc Biol 2005;25:995-1001.
https://doi.org/10.1161/01.ATV.0000159890.10526.1e

39 .Buglioni A, Burnett JC Jr. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta 2015;443:3-8. https://doi.org/10.1016/j.cca.2014.10.027

40 .Kopel T, Kaufman JS, Hamburg N, Sampalis JS, Vita JA (2017) Dember LM. Endothelium-dependent and -independent vascular function in advanced chronic kidney disease. Clin J Am Soc Nephrol2017;12:1588-94.
https://doi.org/10.2215/CJN.12811216

41 .Weiner DE, Tighiouart H, Elsayed EF, et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 2008; 51(2):212-23.
https://doi.org/10.1053/j.ajkd.2007.10.035

42 .Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol 2012;36(4):324-31.
https://doi.org/10.1159/000342390

43 .Xia X, Zhao C, Peng FF, et al. Serum uric acid predicts cardiovascular mortality in male peritoneal dialysis patients with diabetes. Nutr Metab Cardiovasc Dis 2016;26(1):20-6.
https://doi.org/10.1016/j.numecd.2015.10.011

44 .Li M, Hou W, Zhang X, Hu L, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis 2014;232(2):265-70.
https://doi.org/10.1016/j.atherosclerosis.2013.11.051

45 .Wen CP, Cheng TY, Chan HT, Tsai MK, Chung IW, Tsai SP, Wu SB, Wen SF. Is High Serum Uric Acid a Risk

Marker or a Target for Treatment? Examination of Individuals with Low Cardiovascular Risk in a Large Cohort. Am J Kidney Dis 2010;2:53-59.
https://doi.org/10.1053/j.ajkd.2010.01.024

46 .Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 2011;63(1):102-10 https://doi.org/10.1002/acr.20344

47 .Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61(7):885-92. https://doi.org/10.1002/art.24612

48 .Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014;16(1):15-24.
https://doi.org/10.1093/eurjhf/hft132

49 .Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of
Chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018; 40:289-297.
https://doi.org/10.1080/0886022X.2018.1456463

50 .Madero M: High levels of uric acid linked to CKD death risk. Renal Urol News 2008.

51 .Cristobal-Garcia M, Garcia-Arroyo FE, Tapia E. Renal oxidative stress induced by long-
Term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev 2015;2015:535686.

52 .Zazueta C, Johnson RJ, Lozada LG, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1beta expression in human primary renal proximal tubule epithelial cells through the toll-like receptor 4-mediated pathway. Oxidative Med Cell Longev 2015;35(5):1347-54. https://doi.org/10.3892/ijmm.2015.2148

53 .Prasad Sah OS, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review. Nephrourol Mon 2015;7(3):e27233.
https://doi.org/10.5812/numonthly.7(3)2015.27233

54 .Li P, Zhang L, Zhang M, Zhou C, Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: a mechanism for uric acid-induced endothelial dysfunction. Int J Mol Med

2016;37(4):989-97.

https://doi.org/10.3892/ijmm.2016.2491

55 . Fang JI, Wu JS, Yang YC, Wang RH, Lu FH, Chang CJ. High uric acid level associated with increased arterial stiffness in apparently healthy women. Atherosclerosis 2014;236:389-93.

https://doi.org/10.1016/j.atherosclerosis.2014.07.024

56 . Edwards NC, Moody WE, Yuan M, et al. Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease. Am J Cardiol 2015;115(9):1311-7. https://doi.org/10.1016/j.amjcard.2015.02.015

57 . Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010;62(2):170-80. https://doi.org/10.1002/acr.20065

58 . Grossman C, Shemesh J, Koren-Morag N, Bornstein G, Ben-Zvi I, Grossman E: Serum uric acid is associated with coronary artery calcification. J Clin Hypertens 2014;16(6):424-8. https://doi.org/10.1111/jch.12313

59 . Kivity S, Kopel E, Maor E, et al. Association of serum uric acid and cardiovascular disease in healthy adults. Am J Cardiol 2013;111(8):1146-51.

https://doi.org/10.1016/j.amjcard.2012.12.034

60 . Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: a meta-analysis of prospective studies. Atherosclerosis 2013;231(1):61-8. https://doi.org/10.1016/j.atherosclerosis.2013.08.023

61 . Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67(5):1739-42.

https://doi.org/10.1111/j.1523-1755.2005.00273.x

62 . Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH: Oxidative stress with an activation of the renin angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010;28(6):1234-42.

https://doi.org/10.1097/HJH.0b013e328337da1d

63 . Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005;16(12):3553-62. https://doi.org/10.1681/ASN.200